obesity research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-28 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
For a better understanding of the stiffness and strain of resilin, Hooke's law should be taken into consideration. For linear springs, Hooke's law states that the force required to deform the spring is directly proportional to the amount of deformation by a constant which is the characteristic of the spring. A material is viewed as elastic when it can be deformed to a large extend with a limited amount of force. Hydrated resilin has a tensile modulus of 640–2000 kPa, an unconfined compressive modulus of 600–700 kPa, and a strain to break of 300%.
== In history == Coronary occlusion was first discussed in 1910 by Sir William Osler who discussed coronary occlusion during the Lumleian Lectures. In 1912, James Herrick published an article in JAMA documenting his findings on coronary occlusion in animals. According to Robert K. Massie's Nicholas and Alexandra: The Fall of the Romanov Dynasty, Tsar Nicholas II may have suffered a coronary occlusion right before he was toppled from his throne during the Russian Revolution in 1917. Coroners cited a coronary occlusion as the cause of death for Montgomery Clift.
==== Iron recycling and loss ==== Most of the iron in the body is hoarded and recycled by the reticuloendothelial system, which breaks down aged red blood cells. In contrast to iron uptake and recycling, there is no physiologic regulatory mechanism for excreting iron. People lose a small but steady amount by gastrointestinal blood loss, sweating and by shedding cells of the skin and the mucosal lining of the gastrointestinal tract. The total amount of loss for healthy people in the developed world amounts to an estimated average of 1 mg a day for men, and 1.5–2 mg a day for women with regular menstrual periods. People with gastrointestinal parasitic infections, more commonly found in developing countries, often lose more. Those who cannot regulate absorption well enough get disorders of iron overload. In these diseases, the toxicity of iron starts overwhelming the body's ability to bind and store it.
Sources: en.wikipedia.org
This occurred due to DOM being publicly distributed for free in the form of high-dose tablets by LSD distributor Owsley Stanley, who had personally learned of DOM from Shulgin. It is unclear why Shulgin provided information about DOM to Stanley, since doing so had the potential to risk Shulgin's professional career and the DOET clinical studies. One possibility is that Dow Chemical Company was not further looking into DOM and Shulgin thought that it was a promising drug that would otherwise be forgotten. In any case, street use of DOM was short-lived because the tablets caused a public health crisis due to them often producing very long durations (up to 3–4 days), intense experiences, worrying physical side effects, and hospitalizations. DOM was first reported on in the media and scientific literature in 1967 as a result of the crisis. DOM became illegal in the United States in 1968. Dow Chemical Company terminated its clinical research program on DOET due to the DOM public health crisis. DOET was subsequently first described in the literature by Snyder and colleagues in 1968. Snyder continued to be interested in DOET as a potential medicine, but it was never further developed. Snyder also described 2,5-dimethoxyamphetamine (2,5-DMA), which had been synthesized and tested by Shulgin, in the literature in 1968. DOM and DOET were further described in the scientific literature by Shulgin in 1969. In addition, Shulgin discussed DOM, DOET, TMA-2, and 2,5-DMA in a book chapter on hallucinogens published in 1970.
The precipitation ability was enhanced by overexpressing PhoK protein in E. coli. Plants absorb some uranium from soil. Dry weight concentrations of uranium in plants range from 5 to 60 parts per billion, and ash from burnt wood can have concentrations up to 4 parts per million. Dry weight concentrations of uranium in food plants are typically lower with one to two micrograms per day ingested through the food people eat.
In early 1936, Thomas met Caitlin Macnamara (1913–1994), a 22-year-old dancer of Irish and French Quaker descent. She had run away from home, intent on making a career in dance, and aged 18 joined the chorus line at the London Palladium. Introduced by Augustus John, Caitlin's lover, they met in The Wheatsheaf pub on Rathbone Place in London's West End. Laying his head in her lap, a drunken Thomas proposed. Thomas liked to assert that he and Caitlin were in bed together ten minutes after they first met. Although Caitlin initially continued her relationship with John, she and Thomas began a correspondence, and in the second half of 1936 were courting. They married at the register office in Penzance, Cornwall, on 11 July 1937. For the first months of their relationship and marriage the couple lived at the Macnamara family home in Blashford, Hampshire. In May 1938 they moved to Wales, to the village of Laugharne, Carmarthenshire where they rented a cottage in Gosport Street before moving into 'Sea View', a larger property, a couple of months later. They left Laugharne in July 1940 and then led a peripatetic lifestyle over the next few years, returning to Blashford and subsequently living at Marshfield (1940), Bishopston (1940–41), Chelsea, in London (1942–43), Talsarn (1942–44), East Knoyle, Beaconsfield (1944), Bosham, Sussex (1944), Blaencwm (Llansteffan) (1944 and 1945), New Quay (1944–45), and in premises arranged by Margaret Taylor, one of Dylan's benefactors (the wife of the historian A. J. P.
Sources: en.wikipedia.org
== Battle honours == In the British Army, battle honours are awarded to regiments that have seen active service in a significant engagement or campaign, generally with a victorious outcome. The Special Air Service Regiment has been awarded the following battle honours:
=== Early corals === Reef-building organisms similar to modern corals first appeared in the Cambrian about 535 million years ago. Fossils are extremely rare until the Ordovician period, 100 million years later, when Heliolitida, rugose, and tabulate corals became widespread. Paleozoic corals often contained numerous endobiotic symbionts. Tabulate corals occur in limestones and calcareous shales of the Ordovician period, with a gap in the fossil record due to extinction events at the end of the Ordovician. Corals reappeared some millions of years later during the Silurian period, and tabulate corals often form low cushions or branching masses of calcite alongside rugose corals. Tabulate coral numbers began to decline during the middle of the Silurian period. Rugose or horn corals became dominant by the middle of the Silurian period, and during the Devonian, corals flourished with more than 200 genera. The rugose corals existed in solitary and colonial forms, and were also composed of calcite. Both rugose and tabulate corals became extinct in the Permian–Triassic extinction event 250 million years ago (along with 85% of marine species), and there is a gap of tens of millions of years until new forms of coral evolved in the Triassic.
== Academic integrity == SCIRP generated controversy in 2010 when it was found that its journals duplicated papers which had already been published elsewhere, without notification of or permission from the original author and of the copyright holder. Several of these publications have subsequently been retracted. Some of the journals had listed academics on their editorial boards without their permission or even knowledge, sometimes in fields very different from their own. In 2012, one of its journals, Advances in Pure Mathematics, accepted a paper written by a parody generator; the paper was not published, but only due to its author's unwillingness to pay the publication fee. The company has also been noted for the many unsolicited bulk emails it sends to academics about its journals. In 2013, the Open Journal of Pediatrics, a SCIRP journal, published a study which concluded that the number of babies born with thyroid problems in the western United States increased by 16 percent in 2011 compared to 2010, after the Fukushima Daiichi nuclear disaster. The study has been criticized for not taking into account the fact that 2010 was a year with an unusually low number of births with thyroid problems. SCIRP refused to print a letter criticizing the study, but offered to publish it as an article for a charge. The company has been included in a list of questionable open access publishers, according to Jeffrey Beall's criteria. Beall states that "This publisher exists for two reasons.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.